Nirvanol 5 mg
Contraindications: Hypersensitivity to OLANZapine.Pregnancy/Lactation: Unknown if drug crosses placenta or is distributed in breast milk. Children: Safety and efficacy not esTabletlished. Elderly: Use caution. Consider lower starting doses.
PO: Management of manifestations of schizophrenia. Treatment of acute mania
associated with bipolar disorder as monotherapy or in combination with lithium
or valproate. In combination with FLUoxetine: treatment of depressive episodes
associated with bipolar I disorder and treatment of treatment-resistant bipolar
depression. OFF-LABEL: Prevention of
chemotherapy-induced nausea/vomiting. Acute treatment of delirium. Treatment
of anorexia nervosa Tourette?s syndrome tic disorder.
Frequent (26%?10%): Drowsiness agitation insomnia headache
nervousness hostility dizziness rhinitis. Occasional (9%?5%): Anxiety
constipation nonaggressive atypical behavior dry mouth weight gain
orthostatic hypotension fever arthralgia restlessness cough pharyngitis visual
changes (dim vision). Rare: Tachycardia; back chest abdominal or extremity
Adverse effects/toxic reactions
Rare reactions include seizures neuroleptic malignant syndrome a potentially
fatal syndrome characterized by hyperpyrexia muscle rigidity irregular pulse or
B/P tachycardia diaphoresis cardiac arrhythmias. Extrapyramidal symptoms
(EPS) dysphagia may occur. Overdose (300 mg) produces drowsiness slurred
which CNS depression is prominent; cardiac disease hemodynamic insTabletility
prior MI ischemic heart disease; hyperlipidemia pts at risk for aspiration
pneumonia decreased GI motility urinary retention BPH narrow-angle
glaucoma diabetes elderly pts at risk for suicide Parkinson?s disease severe
renal/hepatic impairment predisposition to seizures.